The FDA cleared Eli Lilly’s Onswik (insulin efsitora alfa-gobe) on September 23, making it the second once-weekly basal insulin approved in the United States. The timing matters, but the competitive position matters more. Lilly already holds about 61% share of the U.S. incretin market, runs Mounjaro and Zepbound as the two dominant weight and diabetes drugs in the country, and now adds a weekly insulin to a portfolio that no rival can replicate end to end.
Efsitora is designed to maintain steady basal insulin levels across a full seven-day dosing interval, reducing basal injections from approximately 365 to 52 per year versus once-daily basal insulin. That reduction in injection burden is not a minor convenience feature. Physicians and payers consistently cite poor adherence as the central failure mode in insulin therapy, and a once-weekly format directly attacks it. The QWINT Phase 3 program was designed as a five-trial program spanning type 2 and type 1 diabetes. Across the type 2 program, the studies showed noninferior A1C lowering versus insulin glargine or insulin degludec in the studied populations.
Why Wall Street Is Paying Attention
Onswik lands inside a business that is already firing on every cylinder. In Q2 2026, Lilly reported revenue of about $23.0 billion, up about 48% year over year, with EPS of $8.38; Mounjaro delivered $9.94 billion while Zepbound added $4.93 billion. Full-year revenue guidance was subsequently raised to $85 to $87 billion.
Novo Nordisk is the natural comparison. The FDA approved Novo’s Awiqli (insulin icodec-abae) on March 25, 2026 as the first once-weekly basal insulin in the U.S., and Novo has since launched Awiqli nationally in the U.S. So Novo does have an approved weekly insulin on shelves. The gap is elsewhere: in its Q1 2026 reporting, Novo said adjusted sales, excluding the 340B provision reversal, decreased 4% at constant exchange rates as U.S. pricing eroded. Meanwhile, Lilly’s retatrutide Phase 3 TRIUMPH-1 topline results showed average weight loss of 28.3% at 80 weeks on the 12 mg dose, a level Lilly itself described as long associated with bariatric surgery, and the company has said a BLA submission is planned for Q1 2027.
What’s Driving the Opportunity
The bull case for LLY is now multi-layered in a way it has not been before. Onswik gives Lilly a weekly insulin to compete directly with Awiqli. Mounjaro and Zepbound hold the GLP-1 high ground. Foundayo, the approved oral GLP-1, is now available in the U.S. Each product addresses a different patient segment, and together they create cross-referral dynamics that reinforce the franchise as a whole.
Among Wall Street analysts, the consensus remains broadly constructive on LLY, but specific counts and average price targets vary by data provider and move frequently. The stock closed at roughly $1,184 on September 24, the day after the Onswik FDA clearance.
What Could Go Wrong
The risks are real. In the QWINT-5 trial for type 1 diabetes, efsitora was associated with a higher rate of combined clinically significant or severe hypoglycemia versus degludec during the 52-week treatment period. That backdrop helps explain why Onswik’s U.S. indication is for adults with type 2 diabetes. Pricing has not been disclosed. And near-term financial performance will also depend on the timing of additional regulatory approvals for orforglipron in diabetes and the pace of uptake in new incretin channels. A pharma tariff surprise or wider GLP-1 price concessions from Medicare could shift sentiment across the sector quickly.
The Bottom Line
Lilly’s competitive position in cardiometabolic disease is now structurally wider than at any prior point. Onswik fills the one slot the portfolio was missing. Novo has Awiqli on shelves, but it does not have Mounjaro’s revenue scale, Zepbound’s obesity franchise, an approved oral pill, or retatrutide advancing through late-stage trials. The U.S. decision is the fourth global approval for Onswik for adults with type 2 diabetes, following the EU, Mexico, and Japan. The commercial infrastructure to convert that clearance into revenue is already built. For investors looking for the single stock with the most durable competitive moat in healthcare today, LLY makes the strongest case.
